These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
234 related items for PubMed ID: 35220244
21. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [Abstract] [Full Text] [Related]
22. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls. Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, Pirmisashvili N, Ben-Haim S. Cancer Imaging; 2018 Nov 01; 18(1):39. PubMed ID: 30382889 [Abstract] [Full Text] [Related]
23. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R. Nucl Med Commun; 2020 Nov 01; 41(11):1183-1188. PubMed ID: 32796451 [Abstract] [Full Text] [Related]
24. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse. Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J. Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430 [Abstract] [Full Text] [Related]
25. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. Caglar M, Tuncel M, Yildiz E, Karabulut E. Ann Nucl Med; 2020 Dec 19; 34(12):932-941. PubMed ID: 32975741 [Abstract] [Full Text] [Related]
26. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M. Eur J Nucl Med Mol Imaging; 2016 Nov 19; 43(12):2114-2121. PubMed ID: 27290607 [Abstract] [Full Text] [Related]
27. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis. Shanmugasundaram R, Saad J, Heyworth A, Wong V, Pelecanos A, Arianayagam M, Canagasingham B, Ferguson R, Goolam AS, Khadra M, Kam J, Ko R, McCombie S, Varol C, Winter M, Mansberg R, Nguyen D, Bui C, Loh H, Le K, Roberts MJ. BJU Int; 2024 Feb 19; 133 Suppl 3():25-32. PubMed ID: 37943964 [Abstract] [Full Text] [Related]
28. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW. BJU Int; 2021 Jan 19; 127(1):71-79. PubMed ID: 32524748 [Abstract] [Full Text] [Related]
29. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R. Eur Urol; 2021 Mar 19; 79(3):413-418. PubMed ID: 33341285 [Abstract] [Full Text] [Related]
30. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM. BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168 [Abstract] [Full Text] [Related]
31. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D. BJU Int; 2019 Sep 05; 124(3):401-407. PubMed ID: 31141284 [Abstract] [Full Text] [Related]
32. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. Eur Radiol; 2018 Feb 05; 28(2):610-619. PubMed ID: 28779400 [Abstract] [Full Text] [Related]
33. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. Haran C, McBean R, Parsons R, Wong D. J Med Imaging Radiat Oncol; 2019 Aug 05; 63(4):495-499. PubMed ID: 30972933 [Abstract] [Full Text] [Related]
34. 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions. Kurash MM, Gill R, Khairulin M, Harbosh H, Keidar Z. Sci Rep; 2020 Feb 20; 10(1):3109. PubMed ID: 32080309 [Abstract] [Full Text] [Related]
35. A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT. Bodar YJL, Luining WI, Keizer B, Meijer D, Vellekoop A, Schaaf M, Hendrikse NH, Van Moorselaar RJA, Oprea-Lager DE, Vis AN. Urol Oncol; 2023 Apr 20; 41(4):205.e17-205.e24. PubMed ID: 36588019 [Abstract] [Full Text] [Related]
36. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. Eur Urol; 2016 Oct 20; 70(4):553-557. PubMed ID: 26810345 [Abstract] [Full Text] [Related]
37. Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. Karahan Şen NP, Aksu A, Bozkurt O, Tuna EB, Çapa Kaya G. Nucl Med Commun; 2022 Jan 01; 43(1):86-91. PubMed ID: 34559761 [Abstract] [Full Text] [Related]
38. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer. van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L. BJU Int; 2019 Jul 01; 124(1):62-68. PubMed ID: 30074667 [Abstract] [Full Text] [Related]
39. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ. BJU Int; 2020 Feb 01; 125(2):206-214. PubMed ID: 31680398 [Abstract] [Full Text] [Related]
40. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer. Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T. Nucl Med Commun; 2023 Oct 01; 44(10):864-869. PubMed ID: 37464793 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]